European Medicines Agency renews IPOPI’s mandate

,

The European Medicines Agency (EMA) recently confirmed that IPOPI’s application to renew its mandate on the Patients and Consumers Working Party (PCWP) was successful following a call for candidates for PCWP membership. Further to the EMA’s evaluation of the various candidates’ application dossiers, IPOPI was accepted as a PCWP member for the 2019-2022 mandate.

The Patients and Consumers Working Party (PCWP) is the platform within the European Medicines Agency that facilitates the discussions on topics of relevance to patients and consumers on the one hand and the EMA on the other. The Working Party was established in 2006 and since then, IPOPI has been a member represented by Jose Drabwell, member of the IPOPI Board. As such, Jose has contributed to the discussions on pharmacovigilance, medication errors or advanced therapy medicinal products. The involvement of IPOPI and other patient and consumer organisations in the EMA is key to ensure that the views of patients and consumers are taken into consideration in the pharmaceutical innovation and regulation at European level.